References
- Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11(Suppl 15):S1–86
- Kasiske BL. Clinical correlates to chronic renal allograft rejection. Kidney Int Suppl 1997; 63: S71–4
- Howell DN, Smith SR, Butterly DW, et al. Diagnosis and management of BK Polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999; 68(9): 1279–88
- Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68(5): 635–41
- Kasiske BL, Keane WF. Laboratory assessment of renal disease: clearance, urinalysis, and renal biopsy. In: Brenner BM, ed. Brenner & Rector's the kidney. 6th ed. Philadelphia: WB Saunders, 2000: 1129–70
- Manjunath G, Sarnak MJ, Levey AS. Estimating the glomerular filtration rate: dos and don'ts for assessing kidney function. Postgrad Med 2001; 110(6): 55–62
- Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33(5): 1004–10
- Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11(10): 1910–7
- Jacobs F, Mamzer-Bruneel MF, Skhiri H, et al. Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout. (Letter) Transplantation 1997; 64(7): 1087–8
- Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64(3): 436–43
- Vincenti F, Laskow DA, Neylan JF, et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation: a report of the US Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61(11): 1576–81
- Campana C, Regazzi MB, Buggia I, et al. Clinically significant drug interactions with cyclosporin: an update. Clin Pharmacokinet 1996; 30(2): 141–79
- Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67(7): 1036–42
- Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66(8): 1040–6
- Jassal SV, Roscoe JM, Zaltzman JS, et al. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998; 9(9): 1697–708
- Fishman JA, Rubin RH. Infection in organ- transplant recipients. N Engl J Med 1998; 338(24): 1741–51
- Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol 2000; 20(2): 176–87
- The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157(21): 2413–46
- Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998; 5(Suppl 3): S142–56
- van den Dorpel MA, Ghanem H, Rischen-Vos J, et al. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int 1997; 51(5): 1608–12
- National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89(3): 1333–445
- Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34(1): 1–13
- London NJ, Farmery SM, Will EJ, et al. Risk of neoplasia in renal transplant patients. Lancet 1995; 346(8972): 403–6
- Brunner FP, Landais P, Seiwood NH. Malignancies after renal transplantation: the EDTA-ERA registry experience. European Dialysis and Transplantation Association-European Renal Association. Nephrol Dial Transplant 1995; 10(Suppl 1): S74–80
- Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998; 27(2): 465–83